Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia

Olga Moser; Manuela Krumbholz; Christian Thiede; Josephine T Tauer; Indra Janz; Melchior Lauten; Dagmar Dilloo; Markus Metzler; Meinolf Suttorp

doi:10.1002/pbc.25090

Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia

Olga Moser
, Manuela Krumbholz
, Christian Thiede
, Josephine T Tauer
, Indra Janz
, Melchior Lauten
, Dagmar Dilloo
, Markus Metzler
, Meinolf Suttorp

Research output: Contribution to journal › Article › peer-review

Abstract

Approximately 40% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low-level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re-introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects.

Original language	English
Pages (from-to)	2080-2
Number of pages	3
Journal	Pediatric Blood and Cancer
Volume	61
Issue number	11
DOIs	https://doi.org/10.1002/pbc.25090
Publication status	Published - Nov 2014
Externally published	Yes

Fields of science

302035 Paediatrics and adolescent medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/pbc.25090

Cite this

@article{b2233b41556b4fd0bd4753d9674586cd,

title = "Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia",

abstract = "Approximately 40\% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low-level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re-introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects.",

keywords = "Adolescent, Antineoplastic Agents/therapeutic use, Benzamides/therapeutic use, Child, Fusion Proteins, bcr-abl/genetics, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy, Male, Piperazines/therapeutic use, Protein Kinase Inhibitors/therapeutic use, Pyrimidines/therapeutic use, Remission Induction",

author = "Olga Moser and Manuela Krumbholz and Christian Thiede and Tauer, \{Josephine T\} and Indra Janz and Melchior Lauten and Dagmar Dilloo and Markus Metzler and Meinolf Suttorp",

note = "{\textcopyright} 2014 Wiley Periodicals, Inc.",

year = "2014",

month = nov,

doi = "10.1002/pbc.25090",

language = "English",

volume = "61",

pages = "2080--2",

journal = "Pediatric Blood and Cancer",

issn = "1545-5017",

number = "11",

}

TY - JOUR

T1 - Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia

AU - Moser, Olga

AU - Krumbholz, Manuela

AU - Thiede, Christian

AU - Tauer, Josephine T

AU - Janz, Indra

AU - Lauten, Melchior

AU - Dilloo, Dagmar

AU - Metzler, Markus

AU - Suttorp, Meinolf

PY - 2014/11

Y1 - 2014/11

N2 - Approximately 40% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low-level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re-introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects.

AB - Approximately 40% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low-level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re-introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects.

KW - Adolescent

KW - Antineoplastic Agents/therapeutic use

KW - Benzamides/therapeutic use

KW - Child

KW - Fusion Proteins, bcr-abl/genetics

KW - Humans

KW - Imatinib Mesylate

KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy

KW - Male

KW - Piperazines/therapeutic use

KW - Protein Kinase Inhibitors/therapeutic use

KW - Pyrimidines/therapeutic use

KW - Remission Induction

UR - https://www.scopus.com/pages/publications/84915736394

U2 - 10.1002/pbc.25090

DO - 10.1002/pbc.25090

M3 - Article

C2 - 24810322

SN - 1545-5017

VL - 61

SP - 2080

EP - 2082

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 11

ER -

Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia

Abstract

Fields of science

UN SDGs

Access to Document

Other files and links

Cite this